

ASX ANNOUNCEMENT

RELEASE OF SECURITIES FROM 24 MONTH ESCROW

11 December 2020

In accord with Listing Rule 3.10A, Exopharm Limited (“**Company**”) (ASX: EX1) advises that 35,661,570 fully paid ordinary shares will be released from the 24 month escrow (“**Escrowed Shares**”) on 18 December 2020.

The Company will apply for quotation of the Escrowed Shares in accordance with the ASX Listing Rules.

Approved for release by the Board of Directors of Exopharm.

Sinead Teague
Company Secretary
Exopharm Limited

Company and Media Enquiries:

Dr Ian Dixon, MBA
Founder and Managing Director
P: +61 (0)3 9111 0026
ian.dixon@exopharm.com

Join our mailing list to receive updates:
info@exopharm.com
www.exopharm.com
P: +61 (0)3 9111 0026

Rudi Michelson
Monsoon Communications
rudim@monsoon.com.au
Tel: +61 (0)3 9620 3333

ABOUT EXOPHARM

Exopharm Limited (ASX:EX1) is a clinical-stage Australian exosome medicine company developing naïve exosome products for regenerative medicine and engineered exosomes for new precision medicines.

Exosomes (or EVs) are small particles naturally produced by cells, which deliver therapeutic ‘cargoes’ to other cells to reduce inflammation and promote regeneration. EVs are plentiful in our youth but decline with age. Recent research points to naïve EV medicines as a way to extend the number of healthy, functional years. EVs secreted by stem cells could be used in place of stem-cell therapy with equal or greater benefit without the problems associate with stem-cell therapies.

Engineered EVs (EEVs) are an important emerging technology for the delivery of precision medicines. By altering proteins on the surface of EVs and adding custom cargoes such as RNA and small molecules, EEVs hold promise in a variety of untreatable diseases.

While trillions of EVs are produced by stem cells, the development of EVs as medicines has been hampered by the challenge of purifying EVs. Exopharm owns a purification technology called Ligand-based Exosome Affinity Purification (LEAP). LEAP technology and associated manufacturing know-how places Exopharm as a global leader in this emerging field. Exopharm is a clinical stage company with pending and current trials for wound healing, hearing loss and osteoporosis.